What's New
Promising FTD Gene Therapy from AviadoBio Featured in the UK Guardian
In London’s Docklands, British biotech company AviadoBio is developing a promising gene therapy to treat FTD. The Guardian wrote about the company’s progress on June 13. AviadoBio’s lead therapy, AVB-101,…
FTD Science Digest: Help Advance Science by Joining the Updated FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than…
FTD Research Spotlight: A New Researcher Portal and Other Updates from the FTD Disorders Registry
It is a pivotal time for FTD clinical research. New therapies have advanced to phase 3 clinical trials. Treatments for FTD caused by variants in specific genes are closer than…
AFTD Webinar: Speech Language Therapy — A Promising Practice in FTD Treatment and Care
When patients lose the ability to communicate effectively, doctors and other clinicians often refer them to a speech language pathologist (SLP) to help them regain their speaking skills. But for…
The Lived Experience of FTD: The Challenges of July Fourth
The following article was written by former Persons with FTD Advisory Council member Cindy Odell. The Council works to ensure the voice of people living with FTD guides AFTD as…
Chinese Study Explores the Psychological Well-being and Health of Dementia Caregivers
A study published in the journal BMC Geriatrics explores the self-assessed well-being of informal care partners and professional caregivers who support people with dementia, such as FTD. The study provides…
“Alzheimer’s & Dementia” Publishes Summary of AFTD’s 2022 Holloway Summit
Digital health technologies have the potential to benefit the FTD community by improving accessibility to research and clinical care. Such technologies were the focus of the 2022 Holloway Summit —…
Leonard A. Lauder, 1933-2025
Leonard A. Lauder, a legend of the cosmetics industry who invested hundreds of millions of dollars into research seeking a cure for FTD and other dementias through his Alzheimer’s Drug…
Vesper Bio Clinical Trial for FTD-GRN Treatment Achieves Enrollment Milestone
Danish biotechnology company Vesper Bio announced that it reached a participation milestone in its phase Ib/IIa clinical trial evaluating a treatment for FTD-GRN. Six participants have been enrolled in the…
Advancing Hope: Blood Test for Diagnosing Alzheimer’s Disease Approved by FDA
The United States Food and Drug Administration (FDA) approved the marketing of a blood test to diagnose Alzheimer’s disease. The test, known as the Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain) 
English